PMID- 30974387 OWN - NLM STAT- MEDLINE DCOM- 20190829 LR - 20190829 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 114 DP - 2019 Jun TI - ACE inhibitor suppresses cardiac remodeling after myocardial infarction by regulating dendritic cells and AT(2) receptor-mediated mechanism in mice. PG - 108660 LID - S0753-3322(18)38058-2 [pii] LID - 10.1016/j.biopha.2019.108660 [doi] AB - Dendritic cells (DCs) play a complex role in the progression of myocardial infarction (MI). The impact of angiotensin-converting enzyme (ACE) inhibitor therapy, partly via affecting DCs maturation and recruitment, was tested on a MI mouse model. Furthermore, the cardioprotective effects of ACEI were enhanced through attenuating migration of DCs from the spleen into peripheral circulation, thereby inhibiting DCs maturation and tissue inflammation. ACEI repress DCs immune inflammatory response through down-regulating DCs maturation surface markers and regulating inflammatory cytokines, which led to a higher survival rate, improved function and remodeling through decreased inflammatory response after MI. However, inhibition of AT(2)R activation, resulted in a reduction of ACEI effects on DCs. The potent anti-inflammatory effect of ACEI can partially be attributed to its impact on DCs through activation of AT(2)R, which may provide a new target mechanism for ACEI therapy after MI. CI - Copyright (c) 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Ma, Yuanji AU - Ma Y AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Institute of Cardiovascular Diseases, Shanghai, China. FAU - Yuan, Jie AU - Yuan J AD - Shanghai Institute of Cardiovascular Diseases, Shanghai, China. FAU - Hu, Jialu AU - Hu J AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Institute of Cardiovascular Diseases, Shanghai, China. FAU - Gao, Wei AU - Gao W AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Institute of Cardiovascular Diseases, Shanghai, China. FAU - Zou, Yunzeng AU - Zou Y AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Institute of Cardiovascular Diseases, Shanghai, China. FAU - Ge, Junbo AU - Ge J AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Institute of Cardiovascular Diseases, Shanghai, China. Electronic address: jbge@zs-hospital.sh.cn. LA - eng PT - Journal Article DEP - 20190408 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 0 (Angiotensin Receptor Antagonists) RN - 0 (Angiotensin-Converting Enzyme Inhibitors) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Receptor, Angiotensin, Type 2) SB - IM MH - Angiotensin Receptor Antagonists/pharmacology MH - Angiotensin-Converting Enzyme Inhibitors/*pharmacology MH - Animals MH - Anti-Inflammatory Agents/pharmacology MH - Dendritic Cells/*drug effects MH - Disease Models, Animal MH - Down-Regulation/drug effects MH - Heart/*drug effects MH - Inflammation/drug therapy/metabolism MH - Mice MH - Mice, Inbred C57BL MH - Myocardial Infarction/*drug therapy/metabolism MH - Myocardium/metabolism MH - Receptor, Angiotensin, Type 2/*metabolism MH - Survival Rate MH - Ventricular Remodeling/*drug effects OTO - NOTNLM OT - ACE inhibitor OT - AT(2) receptor OT - Dendritic cell OT - Inflammation OT - Myocardial infarction EDAT- 2019/04/12 06:00 MHDA- 2019/08/30 06:00 CRDT- 2019/04/12 06:00 PHST- 2018/11/13 00:00 [received] PHST- 2019/01/31 00:00 [revised] PHST- 2019/02/01 00:00 [accepted] PHST- 2019/04/12 06:00 [pubmed] PHST- 2019/08/30 06:00 [medline] PHST- 2019/04/12 06:00 [entrez] AID - S0753-3322(18)38058-2 [pii] AID - 10.1016/j.biopha.2019.108660 [doi] PST - ppublish SO - Biomed Pharmacother. 2019 Jun;114:108660. doi: 10.1016/j.biopha.2019.108660. Epub 2019 Apr 8.